Join
Live feed
·
PRReleasevia Quantisnow
Merus N.V. logo

Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

ByQuantisnow·Wall Street's wire, on your screen.
MRUS· Merus N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRUS (Merus N.V.) and more on Quantisnow.